# The Future of Epigenetics: Emerging Technologies and Clinical Applications

## TL;DR

Epigenetics is transforming medicine by linking gene regulation to environmental factors and disease, with new technologies and therapies showing promise across multiple conditions.

## Contribution

This report highlights recent transformative advances in epigenetic research and clinical translation using data from the CAS Content Collection.

## Key findings

- Environmental epigenetics shows how external factors induce heritable changes with transgenerational health implications.
- Cancer research leads epigenetic studies, with 13 FDA-approved drugs targeting hematological malignancies.
- The clinical pipeline includes 37 ongoing trials expanding into metabolic, neurological, and inflammatory disorders.

## Abstract

Epigenetics, the
study of heritable changes in gene expression
that do not involve alterations to the DNA sequence, has emerged as
a transformative field in biology and medicine, revealing how gene
expression is modulated in response to internal and external cues.
Its applications span from understanding fundamental biological processes
and disease mechanisms to developing novel diagnostics and therapies,
making it a cornerstone of modern biomedical research. This report
explores data from the CAS Content Collection to examine recent transformative
advances in epigenetic research, highlighting technological innovations
that are revolutionizing our understanding of gene regulation and
therapeutic applications. Environmental epigenetic research shows
strong interest, demonstrating how external factors induce heritable
epigenetic changes with implications for transgenerational inheritance.
These findings bridge environmental exposures with health outcomes
across generations, informing public health strategies and personalized
medicine approaches. Disease applications span multiple pathologies,
with cancer research leading epigenetic studies. Emerging applications
in aging research, metabolic diseases, and autoimmune conditions demonstrate
the field’s expanding clinical relevance. Clinical translation
has achieved significant success, with 13 FDA-approved epigenetic
drugs primarily targeting hematological malignancies through HDAC
inhibitors (6 drugs) and DNMT inhibitors (2 drugs). The robust clinical
pipeline includes 37 ongoing trials across novel targets, with encouraging
diversification beyond oncology into metabolic, neurological, and
inflammatory disorders.